{"id":"NCT01297309","sponsor":"Shire","briefTitle":"A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)","officialTitle":"A Long-term Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04-06","primaryCompletion":"2018-06-08","completion":"2018-06-08","firstPosted":"2011-02-16","resultsPosted":"2019-08-06","lastUpdate":"2021-05-25"},"enrollment":51,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypoparathyroidism"],"interventions":[{"type":"DRUG","name":"NPSP558","otherNames":["RACE"]}],"arms":[{"label":"NPSP558","type":"EXPERIMENTAL"}],"summary":"This study is a long-term, open-label study using NPSP558 for the treatment of adult patients with Hypoparathyroidism.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Event (TEAE) and Treatment Emergent Serious Adverse Event (TESAE)","timeFrame":"From start of study drug administration up to follow-up (82 months)","effectByArm":[{"arm":"rhPTH (1-84)","deltaMin":13,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":3},"locations":{"siteCount":14,"countries":["United States"]},"refs":{"pmids":["36018496","35974422","35696069","32738041","31369089"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":49},"commonTop":["Muscle spasms","Hypocalcaemia","Sinusitis","Nausea","Paraesthesia"]}}